MarketLens

Has Vanda Pharmaceuticals Finally Found Its Game-Changer with Bysanti

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Has Rivian Finally Found Its Turnaround Catalyst with the R2

6 months ago

Has Urban Outfitters Finally Found Its Stride

6 months ago

Has Redwire Finally Found its Orbit? Truist Thinks So.

5 months ago

Has American Eagle Outfitters (AEO) Finally Found Its Flight Path

6 months ago

Vanda Pharmaceuticals Q2 Earnings Call Highlights

Vanda Pharmaceuticals' Q2 2026 revenue fell 4% to $50.5 million, as Fanapt and PONVORY growth was offset by lower HETLIOZ sales from generic competition and shipment timing. The company reiterated its...

VNDA

Stock News•3 weeks ago

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

FDA approved Takeda's ORZEYFUL (oveporexton), the first oral OX2R agonist for narcolepsy type 1 in adults, addressing the underlying orexin deficiency. This first-in-class approval could expand Takeda...

TAK

Stock News•1 months ago

Veradermics: VDPHL01 Looks Promising Enough On Paper

Veradermics' VDPHL01 shows encouraging early data for male and female hair loss, but still requires pivotal trial results before potential FDA submission. If approved, it would compete as a cash-pay p...

MANE

Stock News•1 months ago

Syntara Limited (PMXSF) Discusses Preliminary Phase II Results for SNT-4728 in Isolated REM Sleep Behavior Disorder Transcript

Syntara Limited discussed preliminary Phase II results for SNT-4728 in isolated REM sleep behavior disorder. The transcript covers early-stage efficacy and safety data from the ongoing trial.

SNT